Prevalence of dyslipidemia in case of diabetes mellitus in Novosibirsk within patients 45-69 age

   Goals. To assess the prevalence of dyslipidemia with increased glycemia fasted and diabetes mellitus(DM) in population with age range from 45 to 69 years of the large industrial center of Western Siberia – Novosibirsk city. Assess the risk of cardiovascular mortality in patients with diabetes and dyslipidemia.

   Materials and methods: During the period from 2003 to 2005 within the frameworks of population screening at HAPIEE project 9360 people were examined inclusive of 4268 men (46 %) and 5094 women (54 %). Examination record included: anthropometry, biochemical parameters definition. Hyperglycemia was diagnosed when the blood plasma fated glucose parameters were ≥ 6.1mmol/L in compliances with NCEP ATP III, 2001 criteria and ≥ 5.6 mmol/L in compliance with criteria IDF, 2005, IDF and AHA/NHLBI (2009). TG of dyslipidemia was equal to ≥1.7 mmol/L, HDL content was < 1.0 mmol/L for men and <1.3 mmol/L for women (NCEPATP III, 2001). The DM was diagnosed when blood glucose fasted levels were equal to ≥ 7.0 mmol/L (WHO, 1999) and when patients with diagnosed diabetes mellitus in anamnesis had normoglycemia. Statistical processing of results was carried out with the help of program package SPSS.

   Results: In Siberian population aged 45–69 for the patients with diabetes mellitus the prevalence of dyslipidemia is rather high: hyper-TG comprised 60,8 %, 59,8 % at men sampling and 61.7 % at women sampling. Chance of developing cardiovascular mortality in the presence giperTG or gipoHS-HDL and SD 2-fold higher than in patients with giperTG or gipoHS-HDL without DM.

   Conclusion: In Siberian population aged 45–69 years for patients with diabetes mellitus the dyslipidemia prevalence is rather high. Chance of developing cardiovascular mortality in the presence giperTG or gipoHS-HDL and SD 2-fold higher than in patients with giperTG or gipoHS-HDL without DM.

1. IDF Diabetes Atlas. Sixth edition 2013; р. 160. URL: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf

2. Никитин Ю. П. Распространенность сахарного диабета у населения Сибири и Дальнего Востока / Ю. П. Никитин [и др.] // Консилиум. – 1999. – № 6. – С. 6–9.

3. Никитин Ю. П. Сахарный диабет и метаболический синдром в Сибири и на Дальнем Востоке / Ю. П. Никитин, М. И. Воевода, Г. И. Симонова // Вест. РАМН. – 2012. – № 1. – С. 66–74.

4. Almdal T., Scharling H., Jensen J. S., Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a popu-lation-based study of 13,000 men and women with 20 years of follow-up // Arch. Int. Med. 2004.Vol. 164. Р. 6–1422.

5. Mooradian A. D. Dyslipidemia in type 2 diabetes mellitus // Nat. Clin. Pract. Endocrinol. Metab. 2009. Vol. 5. P. 9–150.

6. Chahil T. J., Ginsberg H. N. Diabetic dyslipidemia // Endocrinol. Metab. Clin. North Am. 2006. Vol. 35. P. 491–510.

7. Никитин Ю. П. Основные липидные параметры крови жителей Новосибирска / Ю. ПР. Никитин [и др.] // Атеросклероз. – 2012. – Т. 8, № 2. – С. 14–20.

8. Abdel-Maksoud M. F., Hokanson J. E. The complex role of triglycerides in cardiovascular disease // Semin. Vasc. Med. 2002. P. 325–333.

9. Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) // JAMA. 2001. Vol. 285. P. 2486–2497.

10. Alberti K. G. M. M., Robert H., Grundy S. M., Zimmet P. Z. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabe-tes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity // Circulation. 2009. Vol. 120. P. 1640–1645

11. Kannel W. B. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study // Am. Heart J. 1985. Vol. 110. P. 7–1100.

12. Parish S., Offer A., Clarke R., Hopewell J. C., Hill M. R., Otvos J. D., Armitage J., Collins R. R. Heart Protection Study Collaborative Group. Lipids and lipoproteins and risk of different vascular events in the MRC / BHF heart protection study // Circulation. 2012. Vol. 125. P. 78–2469.

13. Фонсека В. Метаболический синдром: пер. с англ. / В. Фонсека. – М.: Практика, 2011. – 272 с.

14. U. K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex // Diabetes Care. 1997. Vol. 20. P. 87–1683.

15. Симонова Г. И. Эпидемиологические предпосылки контроля нарушений углеводного обмена / Г. И. Симонова [и др.] // Актуальные вопросы болезней сердца и сосудов. – 2009. – № 2. – C. 18–23.